p53R2 expression as a prognostic biomarker in early stage non-small cell lung cancer

Hsu,Nan-Yung; Wu,Jeng-Yuan; Liu,Xiyong; Yen,Yun; Chen,Chih-Yi; Chou,Ming-Chih; Lee,Huei; Cheng,Ya-Wen

doi:10.3892/ol_00000108

p53R2 expression as a prognostic biomarker in early stage non-small cell lung cancer

Authors:
- Nan-Yung Hsu
- Jeng-Yuan Wu
- Xiyong Liu
- Yun Yen
- Chih-Yi Chen
- Ming-Chih Chou
- Huei Lee
- Ya-Wen Cheng
View Affiliations

Affiliations: Institute of Medicine, Chung Shan Medical University, 40203 Taiwan, R.O.C.
Published online on: July 1, 2010 https://doi.org/10.3892/ol_00000108
Pages: 609-613

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

p53R2 is a small subunit of ribonucleotide reductase (RR) which has 80% homology to hRRM2 and metastasis-suppressing potential. Previous reports suggested that the expression of p53R2 is used as a prognostic factor and chemotherapy response indicator in several types of cancer. This study aimed to elucidate the association of p53R2 expression and the clinicopathological characteristics of early stage non-small cell lung cancer (NSCLC). Immunohistochemistry was conducted on a tissue array including 92 early stage NSCLC samples. Correlations between p53R2 and clinicopathological factors, recurrence/metastasis and outcomes were analyzed. The analyses showed that there was no correlation between p53R2 expression and the clinicopathological factors. Among disease-free patients during follow-up, patients with p53R2(+) had a better outcome than those with p53R2(−) (P=0.022). By using Cox multivariate regression analysis, p53R2 (risk factor 3.801; 95% CI 1.004-9.454; P=0.044) served as a prognostic biomarker in the prediction of the survival rate for NSCLC patients. Detection of the RR subunit p53R2 may therefore be a useful prognostic marker in early stage NSCLC.

View Figures

View References

1	Montain C: Revision in the International System for Staging Lung Cancer. Chest. 111:1710–1717. 1997. View Article : Google Scholar : PubMed/NCBI
2	WHO. The World Health Organization histological typing of lung tumors. Am J Clin Pathol. 77:123–136. 1982.
3	Reichard P: Ribonucleotide reductases: the evolution of allosteric regulation. Arch Biochem Biophys. 397:149–155. 2002. View Article : Google Scholar : PubMed/NCBI
4	Tanaka H, Arakawa H, Yamaguchi T, et al: A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage. Nature. 404:42–49. 2000. View Article : Google Scholar : PubMed/NCBI
5	Cerqueira N, Pereira S, Fernandes PA and Ramos MJ: Overview of ribonucleotide reductase inhibitors: an appealing target in anti-tumour therapy. Curr Med Chem. 12:1283–1294. 2005. View Article : Google Scholar : PubMed/NCBI
6	Shao J, Zhou B, Zhu L, et al: In vitro characterization of enzymatic properties and inhibition of the p53R2 subunit of human ribonucleotide reductase. Cancer Res. 64:1–6. 2004. View Article : Google Scholar : PubMed/NCBI
7	Guittet O, Hakansson P, Voevodskaya N, et al: Mammalian p53R2 protein forms an active ribonucleotide reductase in vitro with the R1 protein, which is expressed both in resting cells in response to DNA damage and in proliferating cells. J Biol Chem. 276:40647–4051. 2001. View Article : Google Scholar
8	Piao C, Lin M, Kim HB, et al: Ribonucleotide reductase small subunit p53R2 suppresses MEK-ERK activity by binding to ERK kinase 2. Oncogene. 28:2173–2184. 2009. View Article : Google Scholar : PubMed/NCBI
9	Link PA, Baer MR, James SR, et al: p53-inducible ribonucleotide reductase (p53R2/RRM2B) is a DNA hypomethylation-independent decitabine gene target that correlates with clinical response in myelodysplastic syndrome/acute myelogenous leukemia. Cancer Res. 68:9358–9366. 2008. View Article : Google Scholar
10	Liu X, Zhou B, Xue L, et al: Metastasis-suppressing potential of ribonucleotide reductase small subunit p53R2 in human cancer cells. Clin Cancer Res. 12:6337–6344. 2006. View Article : Google Scholar : PubMed/NCBI
11	Furuta E, Okuda H, Aya K and Watabe K: Metabolic genes in cancer: the role in tumor progression and clinical implications. Biochim Biophys Acta. 1805:141–152. 2010.
12	Xu X, Page JL, Surtees JA, et al: Broad overexpression of ribonucleotide reductase genes in mice specifically induces lung neoplasms. Cancer Res. 68:2652–2660. 2008. View Article : Google Scholar : PubMed/NCBI
13	Uramoto H, Sugio K, Oyama T, et al: P53R2, p53 inducible ribonucleotide reductase gene, correlated with tumor progression of non-small cell lung cancer. Anticancer Res. 25:983–988. 2006.PubMed/NCBI
14	Okumura H, Natsugoe S, Yokomalura N, et al: Expression of p53R2 is related to prognosis in patients with esophageal squamous cell carcinoma. Clin Cancer Res. 12:3740–3744. 2006. View Article : Google Scholar : PubMed/NCBI
15	Yanamoto S, Kawasaki G, Yamada S, et al: Ribonucleotide reductase small subunit p53R2 promotes oral cancer invasion via the E-cadherin/beta-catenin pathway. Oral Oncol. 45:521–525. 2009. View Article : Google Scholar : PubMed/NCBI
16	Liu X, Zhou B, Xue L, et al: Ribonucleotide reductase subunits M2 and p53R2 are potential biomarkers for metastasis of colon cancer. Clin Colorectal Cancer. 6:374–381. 2007. View Article : Google Scholar : PubMed/NCBI
17	Zhou BS, Tsai P, Ker R, et al: Overexpression of transfected human ribonucleotide reductase M2 subunit in human cancer cells enhances their invasive potential. Clin Exp Metastasis. 16:43–49. 1998. View Article : Google Scholar : PubMed/NCBI
18	Fan H, Villegas C and Wright JA: Ribonucleotide reductase R2 component is a novel malignancy determinant that cooperates with activated oncogenes to determine transformation and malignant potential. Proc Natl Acad Sci USA. 93:14036–14040. 1996. View Article : Google Scholar
19	Fan H, Huang A, Villegas C and Wright JA: The R1 component of mammalian ribonucleotide reductase has malignancy-suppressing activity as demonstrated by gene transfer experiments. Proc Natl Acad Sci USA. 94:13181–13186. 1997. View Article : Google Scholar : PubMed/NCBI